Biotechnology is helping us tackle challenges such as emerging diseases, the impact of ageing in healthcare, population growth, climate change, and the green transition of the economy. Precision medicines, advanced therapies, mRNA and gene editing technologies are transforming the way diseases can be diagnosed and treated, providing life-saving solutions. Biotechnology is also at the forefront of building a sustainable economy, developing better crops, providing new protein sources, and producing bio-based materials.
Building a new industry and medicine thanks to biotech
OpinionBiotechnology is helping us tackle challenges such as emerging diseases, the impact of ageing in healthcare, population growth, climate change, and the green transition of the economy. Precision medicines, advanced therapies, mRNA and gene editing technologies are transforming the way diseases can be diagnosed and treated, providing life-saving solutions. Biotechnology is also at the forefront of building a sustainable economy, developing better crops, providing new protein sources, and producing bio-based materials.
Crucible Therapeutics spins out with £5m
Latest NewsUniversity of Sheffield spinout gets £5m for gene therapies targeting ALS and FTD, advancing towards clinical trials.
Oxford Biomedica acquires ABL Europe for €15m
Latest NewsOxford Biomedica’s proposed acquisition of ABL Europe from Institut Mérieux, at a consideration of €15m propels global leadership in cell and gene therapy.
Austrian Kern Tec raises €12m in Series A financing
Latest NewsAustrian Kern Tec GmbH has raised €12m in the biggest Series A financing ever seen for a foodtech company in Austria to scale food production from waste.
Austria as a Life Sciences Hotspot
Sponsored PublicationsAustria has gained an outstanding reputation as a research location in the field of life sciences both as a vibrant hub for science and as a cluster for research-oriented and manufacturing companies. The ABA links international companies with this ecosystem
BenevolentAI Ltd inks US$594m partnership with Merck KGaA
Latest NewsBritish drug discovery specialist BenevolentAI Ltd has licenced its end-to-end AI platform capabilities to Merck KGaA to deliver novel drug candidates for three targets in oncology, neurology and immunology.
Aboleris Pharma bags €27.3m in Series A Financing
Latest NewsAutoimmunity specialist AbolerIS Pharma will use a €27.3m Series A Financing to advance its first-in-class antibody inducing immune tolerance in rheumatoid arthritis into the clinic.
German company aims for the first EU approval for cell-cultured meat
Latest NewsThe Cultivated B ist the first company in the world to apply for EU-Novel-Food authorisation of a hotdog made from plant protein and cultivated muscle cells.
Researchers stop brain cell death in Alzheimer’s mice
Latest NewsA Belgian-British research team has identified the human protein underlying necroptosis of human brain cells in Alzheimer’s mice and stopped cell death.
Pierre Fabre Laboratories acquires Vertical Bio
Latest NewsFrench pharma company Pierre Fabre Laboratories has baged Vertical Bio to push development of the company’s NSCLC candidate.
C